Skip to main content
Clinical Trials/NL-OMON38378
NL-OMON38378RecruitingNot Applicable

The role of gut microbiota and chronic inflammation as drivers of cardiovascular disease - Nijmegen Biomedical Study - Non Invasive markers of Atherosclerosis 3 - NBS-NIMA3

niversitair Medisch Centrum Sint Radboud0 sites500 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
500

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - participant NIMA-NBS 2 study
  • - body mass index > 27 kg/m2

Exclusion Criteria

  • - Recent cardiovascular event (myocardial infarction, transient ischemic attack, stroke < 3 months)
  • - History of bariatric surgery or bowel resection
  • - Inflammatory bowel disease
  • - Coagulation defects
  • - Thrombocytopenia (thrombocytes < 100 x 10E9)
  • - Liver dysfunction (INR > 1.6)
  • - Renal dysfunction (estimated glomerular filtration rate < 30 ml/min/1.72m2)
  • - Use of oral or subcutaneous anti-coagulant therapy
  • - Use of thrombocyte aggregation inhibitors other than acetylsalicylic acid or carbasalate calcium
  • - Claustrofobia
  • - Metallic fragments, clips or devices in brain, eyes, spinal canal
  • - Implantable defibrillator or pacemaker (wires)
  • - Mandibular magnetic implants
  • - Neurostimulator, bladder stimulator, non-removable insulin pump
  • - Metal tissue-expander in chest
  • - Cochlear implant
  • - Ossicular replacement prosthesis
  • - Intolerance or allergy for lidocaine

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Similar Trials

The role of gut microbiota and chronic... | Clinical Trial